NCT02658981: Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) |
|
|
| Completed | 1 | 63 | US | Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, BMS-936558, Nivolumab, Pharmacological Study, Laboratory Biomarker Analysis, Anti-CD137, urelumab | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Bristol-Myers Squibb | Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasm | 04/22 | 10/23 | | |
